OraSure Technologies Supports Global and Domestic Rapid HIV Testing Initiatives for World AIDS Day

  
    
  
  
    
      OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral 
      fluid diagnostics, today announced its support of rapid HIV testing 
      initiatives taking place in more than 20 states in the U.S. and several 
      countries globally, in recognition of World AIDS Day, commemorated 
      annually on December 1st. OraSure’s support of these 
      initiatives includes the production of HIV testing promotional 
      materials, complimentary OraQuick ADVANCE® Rapid 
      HIV-1/2 Antibody test kits to be used in conjunction with World AIDS 
      Day, and any necessary product training for newly launched sites.
    
    
      In conjunction with World AIDS Day, AIDS Healthcare Foundation (AHF) is 
      launching a program to test 1 million people around the world in the 
      week leading up to World AIDS Day (www.onemilliontests.org). 
      In support of this program, OraSure has provided a quantity of rapid 
      oral fluid tests in countries where such testing does not currently 
      exist.
    
    
      Now in its 20th year, World AIDS Day is an international day 
      of observance to honor those who have died from AIDS, as well as 
      increase awareness of the disease in hopes of fighting the spread of HIV.
    
    
      “We are pleased to be part of such an important day that brings together 
      people all over the world in the fight against HIV/AIDS,” said Douglas 
      Michels, President and CEO of OraSure Technologies. “OraSure is actively 
      encouraging individuals to learn their HIV status through routine HIV 
      testing – a critical step that enables those who are infected with the 
      virus to receive immediate care and reduce the spread of this disease.”
    
    
      Committed to working in partnership with local, national and 
      international agencies to fight against HIV/AIDS, OraSure is actively 
      supporting testing and education campaigns both domestically and abroad 
      that urge people to learn their HIV status. In the U.S., OraSure is 
      supporting testing events in 20 states and several major cities 
      including Chicago, Philadelphia, and Miami, where clinics and public 
      health sites are implementing rapid oral fluid HIV testing programs with 
      OraQuick ADVANCE®. According to UNAIDS, 33 million people 
      worldwide were living with HIV in 2007. Worldwide, most people living 
      with HIV are unaware that they are infected.
    
    
      The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, 
      manufactured and sold by OraSure Technologies, is the first and only 
      U.S. Food and Drug Administration ("FDA") approved and CLIA (Clinical 
      Laboratory Improvements Amendments Act of 1988) waived rapid 
      point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 
      20 minutes, using oral fluid, finger-stick or venipuncture whole blood 
      and plasma specimens.
    
    
      About OraSure Technologies
    
    
      OraSure Technologies develops, manufactures and markets oral fluid 
      specimen collection devices using proprietary oral fluid technologies, 
      diagnostic products including immunoassays and other in vitro diagnostic 
      tests, and other medical devices. These products are sold in the United 
      States as well as internationally to various clinical laboratories, 
      hospitals, clinics, community-based organizations and other public 
      health organizations, distributors, government agencies, physicians’ 
      offices, and commercial and industrial entities.
    
    
      OraSure Technologies is the leading supplier of oral-fluid collection 
      devices and assays to the life insurance industry and public health 
      markets for the detection of antibodies to HIV. In addition, the Company 
      supplies oral-fluid testing solutions for drugs of abuse testing. For 
      more information on the Company, please go to www.orasure.com.